Therapy of post-COVID-19 syndrome: improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (thiotriazoline)

dc.contributor.authorBelenichev, I.
dc.contributor.authorKucherenko, L.
dc.contributor.authorPavlov, S.
dc.contributor.authorBukhtiyarova, N.
dc.contributor.authorPopazova, O.
dc.contributor.authorDerevianko, N.
dc.contributor.authorNimenko, G.
dc.contributor.authorБєленічев, Ігор Федорович
dc.contributor.authorКучеренко, Людмила Іванівна
dc.contributor.authorПавлов, Сергій Васильович
dc.contributor.authorБухтіярова, Ніна Вікторівна
dc.contributor.authorПопазова, Олена Олександрівна
dc.contributor.authorДерев'янко, Наталя Вікторівна
dc.contributor.authorНіменко, Ганна Романівна
dc.date.accessioned2022-06-27T12:24:04Z
dc.date.available2022-06-27T12:24:04Z
dc.date.issued2022
dc.identifier.citationTherapy of post-COVID-19 syndrome: improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (thiotriazoline) / I. Belenichev, L. Kucherenko, S. Pavlov, N. Bukhtiyarova, O. Popazova, N. Derevianko, G. Nimenko // Pharmacia. - 2022. - Vol. 69. - N 2. - P. 509-516. - https://doi.org/10.3897/pharmacia.69.e82596uk_UK
dc.identifier.issn0428-0296
dc.identifier.urihttps://zsmu.rosbai.com/handle/123456789/16956
dc.language.isoenuk_UK
dc.titleTherapy of post-COVID-19 syndrome: improving the efficiency and safety of basic metabolic drug treatment with tiazotic acid (thiotriazoline)uk_UK
dc.typeArticleuk_UK

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Pharmacia_2022_69_02_509-516.pdf
Size:
807.85 KB
Format:
Adobe Portable Document Format

License bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
license.txt
Size:
2.13 KB
Format:
Plain Text
Description: